Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

Authors not listed

SCRI Development Innovations, LLC · 2012

Abstract

This is a single-arm, Phase II study designed to enroll and treat up to 64 patients. All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length). Patients will receive as an IV infusion bendamustine Days 1 and 2 of Cycles 1 through 6 and ofatumumab Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2 through 6.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-14 MST

Cite this

APA
Anonymous. (2012). Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy. <em>SCRI Development Innovations, LLC</em>. https://clinicaltrials.gov/study/NCT01626352
Vancouver
Anonymous. Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy. SCRI Development Innovations, LLC. 2012.
BibTeX
@misc{anon2012PhaseI, title = {Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy}, author = {Anonymous}, journal = {SCRI Development Innovations, LLC}, year = {2012}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings